BRUSSELS (AP) — The European Union on Tuesday warned pharmaceutical companies that have developed coronavirus vaccines with EU aid that it must get its shots on schedule, a day after the bloc threatened to impose export controls on vaccines produced within its borders.
The EU made it very clear that it is bent on getting all doses as quickly as their contracts provide for at a time when infections are surging, many hospitals are overwhelmed, and many of the 27 members states are struggling to get their vaccine rollout going at top speed.
The hardening of its position came days after it accused AstraZeneca of failing to guarantee the delivery of coronavirus vaccines without a valid explanation. It also had expressed displeasure over vaccine delivery delays from Pfizer-BioNTech. The Pfizer vaccine is already being rolled out in the EU, and the AstraZeneca one is expected to be approved this week.
“Europe invested billions to help develop the world’s first COVID-19 vaccines,” EU Commission President Ursula von der Leyen told the World Economic Forum’s virtual event in Switzerland. “And now, the companies must deliver. They must honor their obligations.”
The EU, which invested 2.7 billion euros in vaccine research and production for the drug companies, “means business,” she added, reflecting the heavy pressure EU nations are under to roll out vaccines.
The EU has committed to buying 300 million AstraZeneca doses with option on 100 million extra shots. Late last week, the company said it was planning to reduce a first contingent of 80 million to 31 million. Pfizer has said it was delaying deliveries to Europe and Canada while it upgrades its plant in Belgium to increase production capacity.
And after two meetings and phone calls the level of distrust that has only grown between the EU and the Anglo-Swedish giant. “We see that doses are being delivered elsewhere and we know that we have signed an agreement,” said Commission spokesman Eric Mamer. More talks with AstraZeneca are set for Wednesday.
That’s why the EU is preparing a system of strict export controls on all coronavirus vaccines produced in the bloc — raising the specter that doses could have trouble leaving the EU until its own orders are fulfilled. The commission insists it is basically to monitor whether companies respect their commitments to the EU.
The biggest EU member state was firmly behind von der Leyen’s view — and batted away any suggestion the EU was looking for special treatment.
“With a complex process such as vaccine production, I can understand if there are production problems — but then it must affect everyone fairly and equally,” German Health Minister Jens Spahn told ZDF television. “This is not about EU first, it’s about Europe’s fair share.”
The EU, which has 450 million citizens and the economic and political clout of the world’s biggest trading bloc, is lagging badly behind countries like Israel and Britain in rolling out coronavirus vaccine shots for its health care workers and most vulnerable people. That’s despite having over 400,000 confirmed virus deaths since the pandemic began.
The slow rollout, however, is hardly only the result of vaccine production issues. France’s rollout was delayed by logistical and administrative problems, including lengthy bureaucratic consent rules designed to allay fears of what authorities believed to be an unusually large number of French vaccine skeptics.
The Netherlands had to scramble to get ready for the hard-to-handle Pfizer-BioNTech vaccine with its requirement for deep freezing. While about 10% of the U.K. population has gotten at least one dose, that figure hovers around 2% overall or lower in a great many EU nations.
Still, the delays in getting vaccines will be make it harder to meet early targets in the EU’s goal of vaccinating 70% of its adults by late summer. French Health Minister Olivier Veran said slow delivery could affect the whole chain. If the calendar is not respected, he said, “then it can change the game.”
A French government official, who demanded anonymity in line with government policy, said the nation is now expecting less than a third of planned deliveries of the AstraZeneca vaccine this quarter — 4.6 million doses, instead of 15.8 million.
The official shrugged off the Pfizer delays, but said the AstraZeneca delays “are much more important” and have “higher stakes” because of the sharply reduced volume over the whole quarter.
“The idea of pre-orders was to get financing to the companies … and ensure stock for the moment of approval. That’s why there is such big disappointment.”
The European Medicines Agency is scheduled to review the Oxford-AstraZeneca coronavirus vaccine Friday and its approval is hotly anticipated. The AstraZeneca vaccine is already being used in Britain and has been approved for emergency use by half a dozen countries, including India, Pakistan, Argentina and Mexico.
Emer Cooke, executive director of the European Medicines Agency, acknowledged concerns across the continent and said the agency was working closely with COVID-19 vaccine makers to consider different manufacturing options to boost production.
“We very much hope these will be short-lived,” she said of the delays.
She said there were only limited options for the EMA to increase capacity, namely, ensuring that new manufacturing sites can be made available “as soon as possible once the country has validated the supply.”
The EU has signed six vaccine contracts for more than 2 billion doses, but only the Pfizer-BioNTech and Moderna vaccines have been approved for use so far.
Geir Moulson and Frank Jordans in Berlin, Mike Corder in The Hague and Angela Charlton in Paris contributed.
Follow all of AP’s pandemic coverage at https://apnews.com/hub/coronavirus-pandemic, https://apnews.com/hub/coronavirus-vaccine and https://apnews.com/UnderstandingtheOutbreak